In the absence of a national Health Technology Assessment (HTA) body in the United States, the Institute for Clinical and Economic Review (ICER) has emerged as a leading voice in evaluating healthcare technologies on their clinical and economic value.
However, given that there is no mandate to base pricing and coverage decisions on ICER assessments, there are many questions about the organisation’s impact.
Since 2018, ICON has conducted annual research with payers to track the role and reach of ICER in payer decision making. Here, we report on the results of our 2020 survey, specifically looking at:
- To what degree are US payers applying ICER findings?
- What are payers’ views on ICER’s methodologies?
- How do ICER reports influence payer practices?
- What do payers view as the pros and cons to adopting Quality Adjusted Life Years (QALYs)
- Are payers implementing value based pricing (VBP)?
